Antagonists of PD-1 and PD-L1 in Cancer Treatment

The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in the tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release the brakes" on anti-tumor immunity and have de...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Seminars in oncology Ročník 42; číslo 4; s. 587 - 600
Hlavní autori: Lipson, Evan J, Forde, Patrick M, Hammers, Hans-Joerg, Emens, Leisha A, Taube, Janis M, Topalian, Suzanne L
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.08.2015
Predmet:
Antineoplastic Agents - therapeutic use
B7-H1 Antigen - antagonists & inhibitors
Biomarkers, Tumor - metabolism
Humans
Immunosuppression - methods
Neoplasms - drug therapy
Neoplasms - metabolism
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Tumor Microenvironment - drug effects
ISSN:1532-8708
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in the tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release the brakes" on anti-tumor immunity and have demonstrated clinical activity in several types of advanced cancers, validating this pathway as a target for cancer therapy. Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for additional cancer types are anticipated. The manageable safety profile of PD-1/PD-L1 blocking drugs identifies them as suitable for outpatient administration and the development of combinatorial therapies. Ongoing studies aim to identify biomarkers to guide patient selection, which would further improve the risk:benefit ratio for these drugs.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:1532-8708
DOI:10.1053/j.seminoncol.2015.05.013